CSL expands relationship with Haemonetics Corporation
CSL•CSL will complete the Haemonetics platform rollout in its U.S. plasma centers by the end of 2027 and has entered an agreement with Terumo BCT to support the transition.
CSL•CSL•CSL•CSL will complete the Haemonetics platform rollout in its U.S. plasma centers by the end of 2027 and has entered an agreement with Terumo BCT to support the transition.
CSL said the transition to the Haemonetics platform is intended to increase efficiency across its plasma collection network.
